David Irwin
Impact in
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments
- Oncology top 1%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
Papers in
- Hematology 42
- Multiple Myeloma Research and Treatments 42
-
- Protein Degradation and Inhibitors 27
- Ubiquitin and proteasome pathways 8
- Cancer therapeutics and mechanisms 4
- Co-authors
- Sundar Jagannath (22 shared papers)Paul G. Richardson (27 shared papers)Kenneth C. Anderson (25 shared papers)James R. Berenson (10 shared papers)Bart Barlogie (7 shared papers)David P. Schenkein (13 shared papers)Melissa Alsina (6 shared papers)Steven Limentani (5 shared papers)
- Journals
- Blood (20 papers)Journal of Clinical Oncology (12 papers)British Journal of Haematology (9 papers)Leukemia (4 papers)Cancer (3 papers)
- Partner nations
- United StatesNetherlandsFrance
In The Last Decade
David Irwin
65 papers receiving 4.1k citations
David Irwin's Hit Papers
Peers
Comparison fields: 5 of 90
- Hematology 2.4k
- Oncology 1.7k
- Internal Medicine 137
- Molecular Biology 2.1k
- Emergency Medical Services 194
Countries citing papers authored by David Irwin
This map shows the geographic impact of David Irwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Irwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Irwin more than expected).
Fields of papers citing papers by David Irwin
This network shows the impact of papers produced by David Irwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Irwin. The network helps show where David Irwin may publish in the future.
Co-authors
The 25 scholars most cited alongside David Irwin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Hit paper breakdown → | 2004 | 569 |
| 2 | 2006 | 483 | |
| 3 | 2005 | 299 | |
| 4 | 2001 | 208 | |
| 5 | 2006 | 183 | |
| 6 | 2005 | 179 | |
| 7 | 2005 | 161 | |
| 8 | 2004 | 138 | |
| 9 | 2008 | 132 | |
| 10 | Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. | 2006 | 122 |
| 11 | 2009 | 120 | |
| 12 | 2004 | 118 | |
| 13 | 2006 | 115 | |
| 14 | 2001 | 108 | |
| 15 | 2001 | 107 | |
| 16 | 2007 | 99 | |
| 17 | 2002 | 98 | |
| 18 | 2005 | 94 | |
| 19 | 2005 | 82 | |
| 20 | 2008 | 75 |
About David Irwin
David Irwin is a scholar working on Hematology, Molecular Biology, Oncology, Genetics and Pulmonary and Respiratory Medicine, having authored 66 papers that have together received 4.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (42 papers), Protein Degradation and Inhibitors (27 papers), Cancer Treatment and Pharmacology (17 papers), Ubiquitin and proteasome pathways (8 papers), HIV/AIDS drug development and treatment (6 papers), Chronic Lymphocytic Leukemia Research (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Cancer therapeutics and mechanisms (4 papers). The work is most often cited by research in Hematology (2.4k citations), Oncology (1.7k citations), Internal Medicine (137 citations), Molecular Biology (2.1k citations) and Emergency Medical Services (194 citations). David Irwin has collaborated with scholars based in United States, Netherlands and France. Frequent co-authors include Sundar Jagannath, Paul G. Richardson, Kenneth C. Anderson, James R. Berenson, Bart Barlogie, David P. Schenkein, Melissa Alsina, Steven Limentani, Raymond Alexanian and David S. Siegel. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Leukemia and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.